International Psoriasis Council
Advancing Knowledge. Improving Care.
Welcome and Program Overview
Lone Skov, MD, PhD, Denmark
Gunnar Lomholt’s Story and Thesis
Claus Zachariae, MD, DMSci, Denmark
Big Data and Implications to Psoriasis
Tamar Nijsten, MD, PhD, Netherlands
What Genetic Association Tells Us About Phenotype: HLA and Beyond
Michael Simpson, MSc, PhD, United Kingdom
BREAK
Comorbidities and Their Causal Relationship
Alex Tsoi, MS, PhD, United States
Linking Genetics with Biological Mechanisms
Johann Gudjonsson, MD, PhD, United States
KEYNOTE: A Genetic Epidemiologic History of Psoriasis
James T. Elder, MD, PhD, United States
BREAK
PART TWO
Inflammatory Memory in Psoriasis
Liv Eidsmo, MD, PhD, Denmark
Immunogenetic Dissection of Pustular Forms of Psoriasis
Hervé Bachelez, MD, PhD, France
KEYNOTE: Where is Psoriatic Arthritis Heading?
Oliver Fitzgerald, MBBCh, BAO, MRCPI, MRCP, FRCPI, MD, Ireland
The History of the Faroe Islands
Erland Viberg Joensen, PhD, Faroe Islands
BREAK
Science and Practice of Therapeutic Drug Monitoring
Catherine Smith, MD, United Kingdom
Treatment Strategies and Targets for Severe Psoriasis
Ulrich Mrowietz, MD, Germany
The Need for Real World Evidence
Lone Skov, MD, PhD, Denmark
60 Years of Psoriasis Therapy: How Things Have Changed
Matthias Augustin, MD, Germany
Closing Comments and Adjourn
Jonathan Barker, MD, FRCP, United Kingdom
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
